###### Key questions

What is already known about this subject?
=========================================

-   The European Society for Medical Oncology---Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 is a validated value scale for solid tumour oncology, but it has not yet been evaluated for the use in haematological malignancies.

What does this study add?
=========================

-   Here, we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on grading of 80 contemporary studies for leukaemia, lymphoma, myeloma and myelodysplastic syndromes.

-   The ESMO-MCBS v1.1 was found to be widely applicable to studies in haematological malignancies, generating scores that were judged as reasonable by European Hematology Association (EHA) experts; however, a small number of studies could either not be graded or were not appropriately graded because of shortcomings related to the differences between haematological and solid tumour malignancies.

How might this impact on clinical practice?
===========================================

-   Based on the findings of this study, ESMO and EHA are committed to develop a version of the score that is robustly validated to grade studies in malignant haematology.

Introduction {#s1}
============

In recent years, rapid developments in haematology research resulted in a considerable expansion of treatment options. The development of instruments to measure clinical benefit is essential in the current scenario where increasing numbers of treatments for haematological malignancies (HMs) are becoming available, often targeting a small and defined subpopulation of patients. For this, several value frameworks have been published by different organisations and institutions taking into account or emphasising different aspects contributing to such an evaluation.[@R1] These frameworks vary in terms of their definition of value, target audience and methodology, and each of them has specific limitations, which should be taken into consideration when interpreting their outputs.[@R2] Until now, value frameworks developed in oncology have not been validated in the setting of HMs.

The European Society for Medical Oncology (ESMO) has developed such a value framework called the ESMO---Magnitude of Clinical Benefit Scale (ESMO-MCBS).[@R3] Initially published in 2015, the scale is a validated and reproducible tool in solid tumour oncology with a particular focus on the *clinical benefit*. The ESMO-MCBS was developed to generate clear, valid and unbiased grading of the magnitude of clinical benefit demonstrated in therapeutic studies that could be used for a number of purposes including public health policy and health technology assessment (HTA), clinical decision-making, medical publication and journalism. The ESMO-MCBS grading highlights those treatments which substantially improve the duration of survival and/or the quality of life (QOL) of patients with cancer and aims to distinguish them from trials demonstrating more limited and sometimes even marginal benefits. The ESMO-MCBS was revised (version 1.1) in 2017, based on feedback and queries from clinicians, patients, researchers and representatives of the pharmaceutical industry, and a dynamic process of internal peer review.[@R4] Version 1.1 incorporates 10 revisions and most importantly allows also for scoring of single-arm studies. The ESMO-MCBS assigns categorical benefit scores to European Medicines Agency (EMA) approved drugs, based on results from 'positive' randomised clinical trials: (1) superiority trials that have demonstrated a statistically significant result for the primary endpoint of the study, or secondary in case of overall survival (OS) and (2) non-inferiority trials, reaching a conclusion of non-inferiority. Primary or secondary endpoints included in the scoring system are OS, progression-free survival (PFS), QOL, treatment toxicity or response rates. In developing the ESMO-MCBS scale, ESMO aspired to meet standards for 'accountability for reasonableness',[@R5] incorporating extensive field testing, statistical modelling[@R7] and peer review of the 'reasonableness' of the generated results into the development process. The ESMO-MCBS is currently incorporated in ESMO's clinical practice guidelines and is being used as part of HTA processes.[@R8]

The European Hematology Association (EHA) and ESMO have developed a joint initiative to develop a version of the ESMO-MCBS that is validated for HMs. As a first step in this process, we have field tested the current version of the ESMO-MCBS (version 1.1) across a wide spectrum of HMs. The aims of this evaluation were (1) to evaluate the scorability of data derived from contemporary clinical trials in HMs, (2) to evaluate the reasonableness of the generated grades for clinical benefit using the current version and (3) to identify shortcomings in the ESMO-MCBS v1.1 that require amendments to improve the efficacy and validity of the scale in grading new treatments in the management of HMs.

Methods {#s2}
=======

Study selection {#s2-1}
---------------

The corresponding disease-oriented EHA scientific working groups identified experts who selected representative treatments currently used in clinical practice with a focus on recently approved drugs and novel strategies, to be evaluated for each of the common haematological malignancies: acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), Hodgkin and non-Hodgkin lymphomas, multiple myeloma (MM) and myelodysplastic syndromes (MDS). The treatments selected underwent a literature search to identify corresponding clinical trials and data.

ESMO-MCBS grading {#s2-2}
-----------------

Identified studies were graded by members of the EHA scientific working groups according to the ESMO-MCBS v1.1 forms[@R4] in accordance with the instructions provided by ESMO. Magnitude of clinical benefit scores range from A to C for treatment strategies with curative intent and 5-1 for treatments with non-curative intent, with scores of A--B and 5-4 relating to a substantial level of clinical benefit. Initial grading by the expert groups were reviewed by the ESMO-MCBS working group for applicability and correctness.

Evaluations {#s2-3}
-----------

For each disease entity, we evaluated the scorability of the evaluated studies and the reasonableness of the derived scores. Based on these findings, we identified shortcomings in the current version of the ESMO-MCBS that either precluded scoring or which generated grading which was considered not to be a reasonable estimation of benefit when such studies were identified.

Results {#s3}
=======

The extensive research concluded in 80 studies, 5 of which had either more than two arms or different publications for the same trial presenting results after longer follow-up times (87 studies and/or comparisons in total). In detail, we have scored 7 studies for AML, 5 studies for ALL, 8 studies for CLL, 4 studies for CML, 23 studies for non-Hodgkin and Hodgkin lymphoma, 23 studies for MM and 10 studies for MDS. The ESMO-MCBS v1.1 tool was applied in all the 87 distinct studies and/or subgroups.

Acute myeloid leukaemia {#s3-1}
-----------------------

*Studies evaluated*: Seven studies were evaluated,[@R10] three in a curative setting and four in a non-curative setting ([table 1](#T1){ref-type="table"}).

###### 

Feasibility testing of the ESMO-MCBS v1.1 for acute myeloid leukaemia (n=7)

  Medication                         Trial Name   Setting                                    Primary Outcome   PFS/EFS/ DFS Control    PFS/EFS/DFS Gain   PFS/EFS/DFS HR               OS Control                OS Gain               OS HR                        RR (DOR)                   QOL   Toxicity             ESMO-MCBS score   ESMO-MCBS form   Reference
  ---------------------------------- ------------ ------------------------------------------ ----------------- ----------------------- ------------------ ---------------------------- ------------------------- --------------------- ---------------------------- -------------------------- ----- -------------------- ----------------- ---------------- -----------
  **SOC±** **midostaurin**           RATIFY       Upfront, FLT3-mutated                      OS                15.5 months (DFS)       11.2 months                                     **25.6** **months**       **49.1** **months**   **0.78 (0.63--** **0.96**)                                                         A                 1                [@R10]
  **SOC±gemtuzumab ozogamicin**      ALFA-0701    Upfront, 50--70 years                      EFS               **17.1% 2** **years**   **23.7%**          **0.58 (0.43--** **0.78**)   41.9% 2 years             11.3%                 0.69 (0.49--0.98) Immature                                    Increased            A                 1                [@R11]
  **SOC±sorafenib (+maintenance**)   SORAML       Upfront                                    EFS               **22% 3** **years**     **18%**            **0.64 (0.45--** **0.91**)   56% 3 years               7%                    Immature                                                      Slightly increased   A                 1                [@R12]
  **Azacitidine versus SOC**         AZA-001      Upfront elderly, low blast count           OS                                                                                        16 months                 8.5 months            0.47 (0.28--0.79)                                             Benefit (+1 point)   5                 2a               [@R13]
  **Decitabine versus SOC**          DACO-016     Upfront, elderly, intermediate/poor risk   OS                                                                                        5 months                  2.7 months            0.82 (0.68--0.99)                                                                  2                 2a               [@R14]
  **LDAC ±** **Volasertib**                       Upfront, unfit                             ORR               2.3 months EFS          3.3 months         0.57 (0.35--0.92)            **5.2** **months**        **2.8** **months**    **0.63 (0.40--** **1.00**)   **31% vs 13%, gain 18%**         Slightly increased   3                 2a               [@R15]
  **Enasidenib**                                  IDH2 mutated, relapsed/refractory          ORR                                                                                       3.3 months (historical)                                                      **40.3% (5.8 months**)                                2                 3                [@R16]

Across all tables, in case there is reported information for multiple endpoints, the evaluated endpoint results are indicated with bold.

DFS, disease-free survival; DOR, duration of response; EFS, event-free survival;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; FLT3, *fms-*like tyrosine kinase 3; IDH2, isocitrate dehydrogenase 2; LDAC, low-dose cytarabine; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life; RR, response rate; SOC, standard of care.

*Scorability*: All studies were published with endpoints and data applicable to the ESMO-MCBS v1.1.

*Reasonableness*: The separation of studies with curative/non-curative intent corresponds closely to the distinction between intensive versus non-intensive chemotherapy regimens which are the terms usually applied in the treatment of AML. Grading effectively distinguished between high benefit treatment strategies in a curative setting and stratified between higher and lower benefit treatments in a non-curative setting.

*Shortcomings:* None identified.

Acute lymphoblastic leukaemia {#s3-2}
-----------------------------

*Studies evaluated*: Five studies were evaluated,[@R17] and these included studies relating to three agents recently approved by EMA for relapsed and refractory ALL ([table 2](#T2){ref-type="table"}).[@R17]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for acute lymphoblastic leukaemia (n=5)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                             Trial name   Setting                                                                                                       Primary outcome                                           PFS/EFS control    PFS/EFS gain      PFS/EFS HR                      OS control                                     OS gain                                     OS HR                                           RR (DOR)                              QOL                   Toxicity                                         ESMO-MCBS score   ESMO-MCBS form   Reference (s)
  -------------------------------------- ------------ ------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------ ----------------- ------------------------------- ---------------------------------------------- ------------------------------------------- ----------------------------------------------- ------------------------------------- --------------------- ------------------------------------------------ ----------------- ---------------- ---------------
  **Blinatumomab versus SOC**            TOWER        Relapsed/refractory                                                                                           OS                                                        12% EFS 6 months   19%               0.55 (0.43--0.71)               **4** **months**                               **3.7** **months**                          **0.71 (0.55--** **0.93**)                      44% vs 25% CRR, gain 19%              Improved (+1 point)                                                    5                 2a               [@R17]

  **Inotuzumab ozogamicin versus SOC**   INO-VATE     Relapsed/refractory                                                                                           OS/CRR                                                    1.8 months         3.2 months        0.45 (97.5% CI: 0.34 to 0.61)   **6.7 months (10% gain in 2-year survival**)   **1 month (13% gain in 2-year survival**)   **0.77 (97.5% CI: 0.58 to 1.03) p=** **0.04**   81% vs 29% CRR, gain 52%              Improved              Veno-occlusive disease 11% in experimental arm   4\*               2a               [@R19]

  **Hyper-CVAD +** **ponatinib**                      Philadelphia chromosome-positive, upfront. Phase II single arm                                                EFS                                                       81% 2 years EFS                                                      80% 2 years                                                                                                                                                                                                                                             Not scoreable                      [@R21]

  **CAR T-cell**\                                     Relapsed/refractory, age \<21 years, single arm                                                               ORR at 3 months                                                                                                                76% 1 year                                                                                                                                 81% ORR                                                     \>30% grade 3/4 cytokine release syndrome        3                 3                [@R22]
  **tisagenlecleucel**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Ponatinib**                          PACE         Philadelphia positive resistant to or side effects with dasatinib or nilotinib, or T315I mutation after TKI   Major haematological response within the first 6 months                      7% at 12 months                                                                                  40% at 12 months                                                                            Major haematological response: 41%\                                                                          2                 3                [@R23]
                                                                                                                                                                                                                                                                                                                                                                                                                                              (3 months)                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Based on \>10% increase in 2 years of OS improvement.

CAR T- cell, chimeric antigen receptor T-cell therapy; CRR, complete remission rate; DOR, duration of response; EFS, event-free survival;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life; RR, response rate; SOC, standard of care; TKI, tyrosine kinase inhibitor.

*Scorability*: Four of the five studies were published with endpoints and data applicable to the ESMO-MCBS v1.1. The only not scoreable study was the single-arm study of ponatinib as add-on to standard of care upfront treatment with curative intent.[@R21]

*Reasonableness*: Both the first-in class bispecific antibody blinatumomab (TOWER trial)[@R17] and the antibody-drug conjugate inotuzumab ozogamicin (INO-VATE trial)[@R19] reached high scores based on positive OS data and favourable QOL data for blinatumomab (ESMO-MCBS v1.1 scores 5 and 4, respectively). The chimeric antigen receptor (CAR) T-cell treatment in children/young adults with relapsed or refractory B-cell ALL was graded with maximal credit of 3 for a single-arm study in a non-curative setting.[@R22] The ponatinib treatment (single-arm PACE trial)[@R23] was assigned grade 2 based on the major molecular response (MMR) in the non-curative setting.

*Reasonableness:* Grading effectively distinguished between high benefit treatment strategies in a curative stetting and stratified between higher and lower benefit treatments in a non-curative setting.

*Shortcomings:* One shortcoming was identified:

1.  The ESMO-MCBS v1.1 does not have a form to grade single-arm treatments with curative intent. This shortcoming precluded scoring in one study[@R21] and may also have been relevant to the grading of CAR T-cell salvage therapy which could also be considered as curative.[@R22]

Chronic lymphocytic leukaemia {#s3-3}
-----------------------------

*Studies evaluated*: Eight studies were evaluated ([table 3](#T3){ref-type="table"}).[@R24]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for chronic lymphocytic leukaemia (n=8)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                   Trial name    Setting                                        Primary outcome           PFS control           PFS gain              PFS HR                                                                             OS control                      OS gain                         OS HR                        RR    QOL                        Toxicity                                             ESMO-MCBS score                             ESMO-MCBS form   Reference(s)
  -------------------------------------------- ------------- ---------------------------------------------- ------------------------- --------------------- --------------------- ---------------------------------------------------------------------------------- ------------------------------- ------------------------------- ---------------------------- ----- -------------------------- ---------------------------------------------------- ------------------------------------------- ---------------- --------------
  **FC±** **R**                                CLL8          Upfront, chemofit                              PFS                       32.9 months           23.9 months           0.59 (0.50--0.69)                                                                  **86 months (66.9% 5 years**)   **\>10% gain at 5** **years**   **0.68 (0.54--** **0.89**)         No difference              Increased                                            4                                           2a               [@R24]

  **FC-R versus**\                             CLL10         Upfront, focus elderly subgroup \>65 years     Non- inferiority in PFS   55.2 months           −13.5 months          Non-inferiority not met neither overall, nor in the \>65 years post hoc subgroup                                                                   Not significant                                               Less toxicity in experimental arm                    Not significant, not eligible for scoring   2c               [@R27]
  **R-bendamustine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Ibrutinib versus**\                        RESONATE-2    Upfront elderly                                PFS                       **18.9** **months**   **8** **months**      **0.16 (0.09--** **0.28**)                                                         85% at 24 months                13%                             0.16 (0.05--0.56) Immature         Improved (abstract only)                                                        3                                           2b               [@R28]
  **chlorambucil**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Obinutuzumab±**\                           CLL11         Upfront elderly not eligible for fludarabine   PFS                       **11.1** **months**   **15.6** **months**   **0.18 (0.13--** **0.24**)                                                         NR                              NA                              0.41 (0.23--0.74) Immature                                    Increased but not meeting criteria for downgrading   3                                           2b               [@R30]
  **chlorambucil**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Ibrutinib versus ofatumumab**              RESONATE      Relapsed/refractory (cross-over allowed)       PFS                       **8.1** **months**    **4+** **months**     **0.11 (0.08--** **0.15**)                                                         81% at 12 months                9% at 12 months                 0.43 (0.24--0.79) Immature         Pending                    \>10% SAE increase (−1 point)                        3                                           2b               [@R31]

  (**\>10% gain at 12 months with plateau**)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **R-Venetoclax versus R-bendamustine**       MURANO        Relapsed/refractory                            PFS                       **17** **months**     **6+** **months**     **0.17 (0.11--** **0.25**)                                                         87% at 24 months                5.30%                           0.48 (0.25--0.90) Immature                                                                                         4                                           2b               [@R33]

  (**\>10% gain at 12 months with plateau**)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Ibrutinib**                                RESONATE-17   Relapsed/refractory with del17p                ORR                       63% at 24 months                                                                                                               75% at 24 months                                                                             64%                              No new safety flags                                  3                                           3                [@R34]

  **Venetoclax**                               M13-982       Relapsed/refractory with del17p                ORR                       72% at 12 months                                                                                                               87% at 12 months                                                                             79%                              No new safety flags                                  3                                           3                [@R35]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

del17p, 17 p deletion;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; FC, fludarabine, cyclophosphamide; NA, not applicable; NR, not reached; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life; R, rituximab; RR, response rate; SAE, serious adverse event.

*Scorability*: CLL is generally a relatively indolent disease with a very long survival---often decades long---and many patients do not need intervention for many years and when treatment is initiated it commonly generates very long periods of remission. For these reasons, PFS is generally the most relevant and measurable primary endpoint. Since CLL is generally not considered to be a curable disease, all scoring was performed using scales for non-curative disease. One study[@R27] could not be scored because the primary objective of non-inferiority with regard to PFS was not met. Moreover, the published results limited to a subcohort of patients older than 65 years, which are relevant for clinical practice (particularly in view of presented toxicity data) did not show non-inferiority and they were derived from a post hoc exploratory analysis.

*Reasonableness*: Overall scoring was considered reasonable with the highest grades being achieved by studies demonstrating either mature OS data[@R24] or PFS gains with long-term plateauing of PFS,[@R33] or compelling PFS gains.[@R28] Grading of the phase III study of ibrutinib versus ofatumumab (RESONATE trial)[@R31] was considered to be low; it was credited for PFS advantage including gain in the tail of the curve but was penalised for toxicity associated with the more prolonged drug exposure in continuous treatment (ESMO-MCBS v1.1 score 3). However, the 9% improvement in OS at 12 months was not credited as these results are deemed immature by the ESMO-MCBS criteria. The benefit of novel agents in populations with high unmet need, like relapsed and refractory patients with CLL carrying deletion in chromosome 17 p, was graded reasonably using form 3 for single-arm studies in a non-curative setting.[@R34]

*Shortcomings:* One shortcoming was identified:

1.  The EHA scientific working group members felt that compelling immature survival benefit ought to be credited even when the median survival of the control arm has not been reached.

Chronic myeloid leukaemia {#s3-4}
-------------------------

*Studies evaluated*: Four landmark trials addressing the use of tyrosine kinase inhibitors imatinib, nilotinib, dasatinib and bosutinib upfront for chronic phase CML were graded.[@R36] Only one of these had mature OS data ([table 4](#T4){ref-type="table"}).[@R38]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for chronic myeloid leukaemia (n=4)

  Medication                                    Trial name   Setting                                              Primary outcome                                                EFS/PFS control     EFS/PFS gain   PFS/ EFS HR                  OS control                 OS gain                    OS HR                      Major CytRR/ MMR           Complete CytRR             MMR                        MR4     MR4.5   QOL                                            Toxicity        ESMO-MCBS score   ESMO-MCBS form   Reference(s)
  --------------------------------------------- ------------ ---------------------------------------------------- -------------------------------------------------------------- ------------------- -------------- ---------------------------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ------- ------- ---------------------------------------------- --------------- ----------------- ---------------- --------------
  **Imatinib versus interferon/cytarabine**     IRIS         Newly diagnosed chronic phase (cross-over allowed)   Initial: PFS/EFS long term: OS                                                                                                                                                                                                                                                                                   Improved                                       Less toxicity                                      [@R36]
  18 months PFS                                 73.5%        18.6%                                                                                                                                                                               **87% vs 35%, gain 52%**   **76% vs 15%, gain 62%**                                                                                    **C/2**                    1/2 c                                                                                                             
  10 years EFS                                  56.6%        23%                                                                                                                 **78.8%**           **4.5%**       **0.74 (0.56--** **0.99**)                                                                                                                                          **B/2**                    1/2 c                                                                                                             
  **Nilotinib 600 or 800 mg versus imatinib**   ENESTnd      Newly diagnosed chronic phase                        Initial primary: MMR at 12 months, secondary: complete cytRR                                                                                                                                                                                                                                                     More cardiovasc. events for nilotinib 800 mg                                     [@R39]           
  12 months 600 mg                                                                                                                                                                                                                                                          80% vs 65%, gain 15%       **44% vs 22%, gain 22%**                                                         **2**                      2c                                                                                                                
  12 months 800 mg                                                                                                                                                                                                                                                          78% vs 65%, gain 13%       **43% vs 22%, gain 21%**                                                         **2**                      2c                                                                                                                
  5 years 600 mg                                92.6%        2.4%                                                 NS                                                             91.7%               2.0%           NS                                                                                 77% vs 60%, gain 17%       **66% vs 42%, gain 24%**   **54% vs 31%, gain 22%**   **2**                      2c                                                                                                                
  5 years 800 mg                                4.3%         0.37 (0.15--0.88)                                    4.5%                                                           0.44 (0.21--0.93)                                               **63% vs 42%, gain 21%**   **52% vs 31%, gain 21%**   **2**                      2c                                                                                                                                                                                                 
  **Dasatinib versus imatinib**                 DASISION     Newly diagnosed chronic phase                        Complete cytRR                                                                                                                                                                                                                                                                                                                                                                  [@R41]                             
  12 months                                                                                                                                                                                                                                                                 **77% vs 66%, gain 11%**   46% vs 28%, gain 18%                                                             **1**                      2c                                                                                                                
  5 years                                                                                                                                                                        90%                 1%             NS                                                                                 76% vs 64%, gain 12%       42% vs 33%, gain 9%                                                                                                                                                                                
  **Bosutinib versus imatinib**                 BFORE        Newly diagnosed chronic phase                        MMR at 12 months                                                                                                                                                                                                                           77% vs 66%, gain 11%       **47% vs 37%, gain 10%**                   **1**                                          2c              [@R43]                             

cardiovasc., cardiovascular; CytRR, cytogenetic response rate;EFS, event-free survival;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; MMR, major molecular response; MR, molecular response; NS, not significant; OS, overall survival; PFS, progression-free survival; QOL, quality of life.

*Scorability*: CML is generally considered an incurable disease, but in a small proportion of cases with deep molecular responses the disease may be eradicated. Thus, when mature survival data were available, CML was scored for both curative and non-curative intent.[@R36] Contemporary studies in CML treatments are conventionally evaluated using molecular response evaluations.[@R44] This differs from the concepts of 'pathological complete response' or 'response rate' which are terms used in the ESMO-MCBS v1.1. Scoring of these studies was only possible by interpreting deep molecular responses (MMR 4--5) as pathological complete responses (form 1) or major responses (form 2 c).[@R39] In one study,[@R36] PFS/event-free survival (EFS) gains could not be credited because the PFS of the control arm was very long and had not reached median PFS after 11 years of follow-up.

*Reasonableness*: In the IRIS study of imatinib versus former standard interferon plus cytarabine, initial scoring at 18 months was credited on the basis of complete cytogenic response for curative intent with a grade of C and improvement in molecular response rate with grade 2.[@R36] At 10-year follow-up, the imatinib scores B for curative intent based on survival improvement. While the grades for curative intent were considered reasonable, the EHA working group considered the ESMO-MCBS grade of 2 for non-curable intent to be too low for the benefits observed.

The remaining studies of nilotinib, dasatinib and bosutinib show minor improvements in complete molecular response rates when compared with imatinib (grade 2) in a non-curative setting.[@R39] None of these agents had mature data beyond 5 years and consequently they were not graded for curative intent.

*Shortcomings:* These relatively low scores for imatinib in the non-curative grading appear to indicate two shortcomings in the ESMO-MCBS v1.1:

1.  When PFS (or EFS) is very long, there is no mechanism to credit strong interim gains when the median PFS of the control arm has not yet been reached.

2.  The surrogacy of complete cytogenic response and level 4--5 MMR, defined as 4 to 5-log reduction in *BCR--ABL1* transcript levels from a standardised baseline, are much stronger surrogates for survival than pathological complete response and response rate in solid tumours.[@R44] Consequently, form 2 c needs to be amended to incorporate evaluation of deep molecular responses.

Indolent non-Hodgkin's, relapsed/refractory setting of non-diffuse large B-cell lymphoma (non-DLBCL) and Hodgkin's lymphoma {#s3-5}
---------------------------------------------------------------------------------------------------------------------------

*Studies evaluated*: Twelve studies of recently approved drugs for indolent non-Hodgkin's, relapsed/refractory setting of non-DLBCL and Hodgkin's lymphoma were evaluated ([table 5](#T5){ref-type="table"}).[@R46]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for indolent non-Hodgkin and relapsed/refractory setting of non-DLBCL and Hodgkin's lymphoma (n=12)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                      Trial name              Setting                                                        Primary outcome                         PFS control   PFS gain      PFS HR                OS control            OS gain                                        OS HR                        RR (DOR)                  QOL                            Toxicity                                                     ESMO-MCBS score   ESMO-MCBS form   Reference(s)
  ----------------------------------------------- ----------------------- -------------------------------------------------------------- --------------------------------------- ------------- ------------- --------------------- --------------------- ---------------------------------------------- ---------------------------- ------------------------- ------------------------------ ------------------------------------------------------------ ----------------- ---------------- --------------
  **Obinutuzumab-Chemo versus R-Chemo**           GALLIUM                 Follicular lymphoma, first line                                PFS                                     73%\          7%            0.66 (0.51--0.85)                                                                                                                                                                                                                             Not scoreable     2b               [@R46]
                                                                                                                                                                                 (3 years)                                                                                                                                                                                                                                                                                                    

  **VR-CAP versus R-CHOP**                        LYM-3002                Mantle cell lymphoma first line, not eligible for transplant   PFS                                     14.4 months   10.3 months   0.63 (0.5--0.79)      **55.7** **months**   **35** **months**\                             **0.66 (0.51--** **0.85**)                                                            Increased in experimental arm                                A/4               1/2a             [@R47]
                                                                                                                                                                                                                                                         (**7 year survival gain \>5% with plateau**)                                                                                                                                                                                         

  **R-Bendamustine versus R-CHOP/R-CVP**          BRIGHT study            Indolent and mantle cell lymphoma, first line                  Non-inferiority in CRR (margin: 0.88)                                                                                                                                                       Non-inferiority met\      Improved                                                                                    Not scoreable     2c               [@R49]
                                                                                                                                                                                                                                                                                                                                     1.26 (0.93--1.73)\                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                     31% versus 25%, 6% gain                                                                                                                                  

  **R-Bendamustine versus R-CHOP**                STiL Trial NHL 1-2003   Indolent and mantle cell lymphoma, first line                  Non-inferiority in PFS (margin: 1.32)   31.2 months   38.3 months   0.58 (0.44--0.74)\                                                                                                                                                               Less adverse events in experimental arm                      4                 2c               [@R51]
                                                                                                                                                                                                             Non-inferiority met                                                                                                                                                                                                                                                              

  **Bendamustine±**\                              GADOLIN                 Rituximab-refractory indolent non-Hodgkin's lymphoma           PFS                                     14.9 months   NA            0.55 (0.40--0.74)     **NR**                **\>10% at 5** **years**                       **0.67 (0.47--** **0.96**)                             Delayed deterioration in QOL                                                                5                 2a               [@R52]
  **Obinutuzumab**                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Ibrutinib versus Temsirolimus**                                       Relapsed/refractory mantle cell lymphoma                       PFS                                     6.2 months    8.4 months    0.43 (0.32--0.58)                                                                                                                                 Improved (+1 point)                                                                         4                 2b               [@R55]

  **Lenalidomide versus Investigator's choice**   MCL-002 SPRINT          Relapsed/refractory mantle cell lymphoma                       PFS                                     5.2 months    3.5 months    0.61 (0.44--0.84)                                                                                                                                 Improved (+1 point)                                                                         4                 2b               [@R56]

  **Ibrutinib**                                   PCYC-1104-CA            Relapsed/refractory mantle cell lymphoma                       ORR                                     13.9 months                                                                                                                                         68%                                                                                                                   3                 3                [@R57]

  **Ibrutinib**                                                           Relapsed/refractory marginal zone lymphoma                     ORR                                     14.2 months                                                                                                                                         48%                                                      Relevant toxicity but not meeting criteria for downgrading   3                 3                [@R58]

  **Idealisib**                                   DELTA (101-09)          Relapsed/refractory indolent lymphoma                          ORR                                     11 months                                                                                                                                           57% (12.5 months)                                                                                                     3                 3                [@R59]

  **Pembrolizumab**                               KEYNOTE-\               Relapsed/refractory Hodgkin lymphoma                           ORR                                                                                                                                                                                         69%                       Improved (+1 point)                                                                         4                 3                [@R60]
                                                  087                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Nivolumab**                                   Check\                  Relapsed/refractory Hodgkin lymphoma                           ORR                                     14.7 months                                                                                                                                         69%                       Improved (+1 point)                                                                         4                 3                [@R61]
                                                  Mate 205                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

chemo, chemotherapy; CRR, complete response rate;DLBCL, non-diffuse large B-cell lymphoma; DOR, duration of response;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; NA, not applicable; NR, not reached; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life; R, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine and prednisone; RR, response rate; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone.

*Scorability*: In one of the studies,[@R46] PFS/EFS gains could not be graded because the PFS of the control arm was very long, the median PFS was not reached and only interim gains were reported. The BRIGHT study could not be scored because form 2 c makes no provision for scoring of non-inferiority studies based on response rates.[@R49] The remaining 10 studies were published with endpoints and data applicable to the ESMO-MCBS v1.1 and were all evaluable.

*Reasonableness*: The grading was applicable and was judged by the EHA working group to be reasonable in the evaluated trials, endorsing relatively high benefit grades, that is, ESMO-MCBS v1.1. scores of 4--5 for 7 of the 10 evaluable studies.

*Shortcomings:* Two shortcomings were observed:

1.  The ESMO-MCBS v1.1 has no mechanism for scoring non-inferiority studies based on response rate.

2.  When PFS (or EFS) is very long, there is no mechanism to credit strong interim gains when the median PFS of the control arm has not yet been reached.

Diffuse large B-cell lymphoma {#s3-6}
-----------------------------

*Studies evaluated*: Eleven studies were evaluated[@R63]; two in the first-line setting with curative intent,[@R63] two intensified therapies for first-line and salvage setting, respectively, with both curative and non-curative intent,[@R67] two single-arm studies of CAR T-cell salvage therapy[@R70] and five in a non-curative setting for relapsed and refractory disease ([table 6](#T6){ref-type="table"}).[@R69]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for DLBCL (n=11)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                      Trial name       Setting                                                            Primary outcome                         PFS/EFS/DFS control   PFS/EFS/DFS gain      PFS/EFS/DFS HR               OS control             OS gain     OS HR                RR (DOR)                            QOL        Toxicity                                            ESMO-MCBS score   ESMO-MCBS form   Reference(s)
  ----------------------------------------------- ---------------- ------------------------------------------------------------------ --------------------------------------- --------------------- --------------------- ---------------------------- ---------------------- ----------- -------------------- ----------------------------------- ---------- --------------------------------------------------- ----------------- ---------------- --------------
  **CHOP±** **R**                                 MInT study       First-line DLBCL, stage II--IV or I with bulky disease, IPI 0--1   EFS                                     55.8% (6 years)       18.5%                 p\<0.0001                    **80% (6 years**)      **10.1%**   **p=** **0.0004**                                                                                                       A                 1                [@R63]

  **CHOP±** **R**                                 LNH-98.5         First-line DLBCL, stage II--IV, age 60--80                         PFS                                     20% at 10 years       16.5%                 p\<0.0001                    **27.6% (10 years**)   **15.9%**   **p\<** **0.0001**                                                                                                      A                 1                [@R65]

  EFS                                             38% at 2 years   19%                                                                p\<0.001                                                                                                                                                                                                                                                                                                       

  **R-CHOP ±lenalidomide**\                       REMARC           First-line DLBCL, stage II--IV, age 60--80                         PFS                                     58.9 months           4+ months             0.71 (0.54--0.93)                                               NS                                                                                                                      A/3               1/2b             [@R67]
  **maintenance**                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **R-GDP+ASCT **\                                NCIC-CTG LY12    Relapsed/refractory aggressive lymphoma                            Non- inferiority (ORR) (margin: −10%)                                               No difference                                                   No difference        ORR difference: −1.2 (-9, 6.7)\     Improved                                                       B/not scoreable   1/2 c            [@R68]
  **versus R-DHAP**\                                                                                                                                                                                                                                                                                           44% vs 45% (non- inferiority met)                                                                                                     
  **+ASCT**                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Pixantrone versus investigators' choice**                      Relapsed/refractory aggressive lymphoma                            CRR                                     **2.6** **months**    **2.7** **months**    **0.60 (0.42--** **0.86**)                                                           20% vs 6%, gain 14%                                                                                3                 2b               [@R69]

  **\>10% gain at 12 months, no plateau**                                                                                                                                                                                                                                                                                                                                                                                                            

  **CAR T-cell Axicabtagene ciloleucel**          ZUMA-1           Relapsed/refractory aggressive non-Hodgkin's lymphoma              ORR                                                                                                                                                                      82%                                            Toxicity but not meeting criteria for downgrading   3                 3                [@R70]

  **CAR T-cell Tisagen-lecleucel**                JULIET           Relapsed/refractory DLBCL                                          ORR                                                                                                                                                                      52% (not reached, \>10 months)                 Toxicity not meeting criteria for downgrading       3                 3                [@R71]

  **Lenalidomide versus investigators' choice**   DLC-001          Relapsed/refractory DLBCL                                          ORR                                      **2** **months**      **1.4** **months**   **0.64 (0.41--** **0.99**)                                                           28% vs 12%, gain 16%                           More PFS-improvement in ABC subtype                 2                 2b               [@R72]

  **Panobinostat with or without R**                               Relapsed/refractory DLBCL                                          ORR                                                                                                                                                                      28% (15 months)                                                                                    3                 3                [@R73]

  **Brentuximab vedotin**                                          Relapsed/refractory DLBCL                                          ORR                                     4 months                                                                                                                         44%                                                                                                2                 3                [@R74]

  **Ibrutinib**                                                    Relapsed/refractory DLBCL, subgroup ABC subtype                    ORR                                     2 months                                                                                                                         37% (4.8 months)                                                                                   1                 3                [@R75]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASCT, autologous stem cell transplantation; CART- cell, chimeric antigen receptor T-cell therapy; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CRR, complete response rate; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; DOR, duration of response; EFS, event-free survival;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; IPI, International Prognostic Index; NS, not significant; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life;R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-DHAP, rituximab, dexamethasone, cytarabine and cisplatin; R-GDP, rituximab, gemcitabine, dexamethasone and cisplatin; RR, response rate.

*Scorability*: All studies incorporated required data for evaluation using the ESMO-MCBS v1.1. Single-arm studies of CAR T-cell therapy for refractory or resistant disease[@R70] could not be evaluated for curative intent. The NCIC-CTG LY12 trial could not be graded in the non-curative setting because non inferiority was evaluated on the basis of overall response rate.[@R68]

*Reasonableness*: The grading was applicable and was judged by the EHA working group to be reasonable in the evaluated trials, endorsing high benefit grades for first-line therapies with curative intent.[@R63] Lower benefit scores for trials in the relapsed and refractory therapies were considered reasonable.

*Shortcomings:* One shortcoming was identified:

1.  The ESMO-MCBS v1.1 does not have a form to grade single-arm treatments with curative intent and this shortcoming does not allow for the representation of the full potential benefit of CAR T-cell salvage therapy.[@R70]

Multiple myeloma {#s3-7}
----------------

*Studies evaluated*: [Table 7](#T7){ref-type="table"} describes results from eight studies in the first-line setting.[@R76] Of these, three were conducted for autologous stem cell transplantation (ASCT) eligible[@R76] patients and five are for ASCT ineligible patients.[@R79] [Table 8](#T8){ref-type="table"} describes the results of a further 15 studies with relapsed or refractory myeloma.[@R85]

###### 

Feasibility testing of the ESMO-MCBS v1.1 for first-line multiple myeloma (n=8)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                            Trial name                   Setting           Primary outcome                   PFS/DFS control                    PFS/DFS gain                 PFS/DFS HR                   OS control                     OS gain             OS HR                        RR                                     QOL   Toxicity                                                               ESMO-MCBS score   ESMO-MCBS form   Reference(s)
  ----------------------------------------------------- ---------------------------- ----------------- --------------------------------- ---------------------------------- ---------------------------- ---------------------------- ------------------------------ ------------------- ---------------------------- -------------------------------------- ----- ---------------------------------------------------------------------- ----------------- ---------------- --------------
  **VTD versus TD or VBMCP/VBAD/B**                     GEM2005-less65 PETHEMA/GEM   ASCT eligible     CR post ASCT (PFS)                                                                                                                                                                                                                                          More neuropathy but not meeting criteria for downgrading                                 1/2b             [@R76]

  TD                                                    28.2 months                  28.0 months       p=0.01                            65% at 4 years                     9%                           NS                           **CRR 46% vs 24%, gain 22%**   C/not scoreable                                                                                                                                                                                         

  VBMCP/VBAD/B                                          35.3 months                  20.9 months       p=0.01                            70% at 4 years                     4%                           NS                           **CRR 46% vs 38%, gain 8%**    NEB/not scoreable                                                                                                                                                                                       

  **VTD versus TD**                                     GIMEMA 2005                  ASCT eligible     CR post induction (PFS)           **56% at 3** **years**             **12%**                      **0.63 (0.45--** **0.88**)   84% at 3 years                 2%                  NS                           (near) CRR 31% vs 11%, gain 20%              More neuropathy but not meeting criteria for downgrading               C/not scoreable   1/2b             [@R77]

  **VCD versus PAD**                                    MM5                          ASCT eligible     Non-inferiority of ≥VGPR rates\                                                                                                                                                                                VGPR difference: 2.8%\                       SAEs higher in the control arm                                         Not scoreable     1/2 c            [@R78]
                                                                                                       (margin: −10%)                                                                                                                                                                                                 (−6.8% to 12.3%) non-inferiority met                                                                                                                   

  **VMP versus MP**                                     VISTA                        ASCT ineligible   TTP                               16.6 months                        7.4 months                   0.48\                        **43.1** **months**            **13** **months**   **0.70 (0.57--** **0.85**)                                                                                                                       4                 2a               [@R79]
                                                                                                                                                                                                         (p\<0.001)                                                                                                                                                                                                                                                          

  **VMPT versus VMP**                                   GIMEMA VMPT                  ASCT ineligible   PFS                               **27 months 41% at 3** **years**   **\>13 months 15%**          **0.67 (0.50--** **0.90**)   87% at 3 years                 2%                  NS                                                                  --    Vascular and cardiac events increased in experimental arm (−1 point)   2                 2b               [@R81]

  **Lenalidomide-d continuous versus x18 or MPT x12**   FIRST                        ASCT ineligible   PFS                                                                                                                                                                                                                                                                                                                                                                   [@R82]

  Len-d x18                                             20.7 months                  4.8 months        0.70 (0.60--0.82)                 **56% at 4** **years**             **3% gain at 4** **years**   **NS**                       3                              2b                                                                                                                                                                                                      

  MPT                                                   21.2 months                  4.3 months        0.72 (0.61--0.85)                 **47** **months**\                 **7** **months**\            **0.78 (0.64--** **0.96**)   4                              2a                                                                                                                                                                                                      
                                                                                                                                         **51% at 4** **years**             **8% gain at 4** **years**                                                                                                                                                                                                                                                                       

  **VMP ±** **daratumumab**                             ALCYONE                      ASCT ineligible   PFS                               18 months\                         9+ months\                   0.50 (0.38--0.65)                                                                                                                                         More infections but not meeting criteria for penalty                   3                 2b               [@R83]
                                                                                                                                         50% at 18 months                   21% at 18 months                                                                                                                                                                                                                                                                                 

  **Lenalidomide-d ±** **bortezomib**                   SWOG S07777                  ASCT ineligible   PFS                               30 months                          13 months                    0.71 (0.56--0.91)            **64** **months**              **11** **months**   **0.71 (0.52--** **0.96**)                                                Slightly increased                                                     4                 2a               [@R84]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASCT, autologous stem cell transplantation; CR, complete remission; CRR, complete remission rate; d, dexamethasone; DFS, disease-free survival;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; Len-d, lenalidomide-d; MP, melphalan and prednisone; MPT, melphalan, prednisone and thalidomide; NEB, no evaluable benefit; NS, not significant; OS, overall survival; PAD, bortezomib, doxorubicin, dexamethasone;PFS, progression-free survival; QOL, quality of life; RR, response rate; SAE, serious adverse event; TD, thalidomide and dexamethasone; TTP, time to progression; VBMCP/VBAD/B, vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib; VCD, bortezomib, cyclophosphamide, dexamethasone; VGPR, very good partial response rate; VMP, bortezomib, melphalan and prednisone; VMPT, bortezomib, melphalan, prednisone and thalidomide; VTD, bortezomib, thalidomide and dexamethasone.

###### 

Feasibility testing of the ESMO-MCBS v1.1 for relapsed/refractory multiple myeloma (n=15)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                                  Trial name        Setting                                           Primary outcome                   PFS control                     PFS gain                        PFS HR                       OS control            OS gain              OS HR                        RR (DOR)                     QOL                        Toxicity                           ESMO-MCBS score   ESMO-MCBS form   Reference(s)
  ------------------------------------------- ----------------- ------------------------------------------------- --------------------------------- ------------------------------- ------------------------------- ---------------------------- --------------------- -------------------- ---------------------------- ---------------------------- -------------------------- ---------------------------------- ----------------- ---------------- --------------
  **Dexamethasone ±** **lenalidomide**        CC-5013- MM-010   Relapsed/refractory                               TTP                               **4.7** **months**              **6.6** **months**              **0.35 (0.27--** **0.46**)   20.6 months           NA                   0.66 (0.45--0.96)                                                                                                       3                 2b               [@R85]

  **Lenalidomide-d ±** **carfilzomib**        ASPIRE            Relapsed/refractory                               PFS                               17.6 months                     8.7 months                      0.69 (0.57--0.83)            **40.4** **months**   **7.9** **months**   **0.79 (0.67--** **0.95**)                                Improved (+1 point)        Slightly increased                 4                 2a               [@R86]

  **Lenalidomide-d ±** **ixazomib**           TOURMALINE-MM1    Relapsed/refractory                               PFS (interim)                     14.7 months                     5.9 months                      0.74 (0.59--0.94)                                                       Immature                                                  Not improved                                                  3                 2b               [@R88]

  **Lenalidomide-d ±** **daratumumab**        POLLUX            Relapsed/refractory                               PFS (interim)                     18.4 months                     16+months                       0.37 (0.27--0.52)                                                       Immature                                                                             Higher haematological toxicities   3                 2b               [@R89]

  **Lenalidomide-d ±** **elotuzumab**         ELOQUENT-2        Relapsed/refractory                               Coprimary PFS and ORR (interim)   14.9 months 57% at 12 months    4.5 months 11% at 12 months     0.70 (0.57--0.85)            **39.6** **months**   **8.7** **months**   **0.78 (0.63--** **0.96**)                                No difference              Slightly higher SAEs               3                 2a               [@R90]

  **Dexamethasone ±** **bortezomib**          APEX              Relapsed/refractory                               TTP                               **3.5** **months**              **2.7** **months**              **0.55** (p**=0.001**)       23.7 months           6.1 months           0.77 (p=0.027)                                                                                                          3                 2b               [@R92]

  **Carfilzomib-d versus bortezomib-d**       ENDEAVOR          Relapsed/refractory                               PFS                               9.4 months                      9.3 months                      0.53 (0.44--0.65)            **40** **months**     **7.6** **months**   **0.79 (0.65--** **0.96**)                                Improved (abstract only)   Slightly higher SAEs               3                 2a               [@R94]

  **Bortezomib-d ±** **daratumumab**          CASTOR            Relapsed/refractory                               PFS                               7.1 months 26.9% at 12 months   9.6 months 33.8% at 12 months   0.31 (0.24--0.39)                                                       Immature                                                                             Higher haematological toxicity     3                 2b               [@R96]

  **Bortezomib-d ±panobinostat**              PANORAMA1         Relapsed/refractory                               PFS                               **8.1** **months**              **3.9** **months**              **0.63 (0.52--** **0.76**)   30.4 months           3.25 months          Immature                                                                             3% increase in PN grade ≥3\        2                 2b               [@R98]
                                                                                                                                                                                                                                                                                                                                                                                 (−1 point)                                                            

  **Dexamethasone ±** **pomalidomide**        MM-003            Relapsed/refractory                               PFS                               1.9 months                      2.1 months                      0.48 (0.39--0.60)            **8.1** **months**    **4.6** **months**   **0.74 (0.56--** **0.97**)                                                                                              4                 2a               [@R99]

  **Pomalidomide-d ±** **cyclophosphamide**   MMC-16705         Relapsed/refractory ≥2 prior lines of treatment   ORR                               4.4 months                      5.1 months                      NS                                                                                                   64.7% vs 38.9%, gain 25.8%                                                                 2                 2c               [@R100]

  **Daratumumab**                             SIRIUS            Relapsed/refractory                               ORR                               3.7 months                                                                                                                                                           29% (7.4 months)                                                                           2                 3                [@R101]

  **Daratumumab**                             GEN501            Relapsed/refractory (16 mg/kg)                    Safety                            5.6 months                                                                                                                                                           36% (NR)                                                                                   2                 3                [@R102]

  **Daratumumab +pomalidomide + d**           MMY1001           Relapsed/refractory ≥2 prior lines of treatment   Safety                            8.8 months                                                                                   17.5 months                                                             60% (\>13 months)                                                                          3                 3                [@R103]

  **Pomalidomide +bortezomib + d**            MC1082            Relapsed/refractory                               ORR                               13.7 months                                                                                                                                                          86%                                                                                        3                 3                [@R104]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

d, dexamethasone; DOR, duration of response;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; NA, not applicable;NR, not reached; NS, not significant; ORR, overall response rate; OS, overall survival;PFS, progression-free survival; PN, polyneuropathy; QOL, quality of life; RR, response rate; SAEs, serious adverse events; TTP, time to progress.

*Scorability*: Most studies incorporated required data for evaluation using the ESMO-MCBS v1.1. The PETHEMA/GEM study comparing VTD (bortezomib, thalidomide and dexamethasone) to TD (thalidomide and dexamethasone) or VBMCP/VBAD/B (vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib) as induction therapies did not report HRs for the PFS, resulting in precluded scoring with non-curative intent using form 2b.[@R76] The GIMEMA 2005 study could not be scored for non-curative intent because the median PFS of the control arm had not yet been reached.[@R77] The MM5 non- inferiority study[@R78] could not be scored for non-curative intent because non-inferiority was based on response rate.

*Reasonableness*: First-line treatments for patients who are ASCT eligible are graded both for curative and non-curative intent. The relatively low grades of C for curative intent achieved in two of the ASCT eligible studies[@R76] reflect the prevailing consensus that MM is rarely cured. In most studies evaluated, the scale was feasible and the results were consistent with clinical practice.

*Shortcomings:* Three previously described shortcomings influenced scoring for a small number of these studies.

1.  The ESMO-MCBS v1.1 has no mechanism for scoring non-inferiority studies in a non-curative setting based on response rate.

2.  When PFS (or EFS) is very long, the ESMO-MCBS v1.1 has no mechanism to credit strong interim gains when the median PFS of the control arm has not yet been reached.

3.  The EHA working group members felt that the capitation of PFS at a maximal preliminary grade of 3, with provision for an upgrade based on tail of the curve only if there is a plateau in the study medication PFS with gain of \>10% at 12 months, may have undervalued some MM treatments.[@R96] The plateau requirement for this adjustment precludes credit for substantial prolonged gains in PFS in this disease entity.

Myelodysplastic syndrome {#s3-8}
------------------------

*Studies evaluated*: Ten studies were evaluated in this setting.[@R105] Of these, two studies were evaluated based on OS or PFS and the remaining eight studies were evaluated based on response rate ([table 9](#T9){ref-type="table"}).

###### 

Feasibility testing of the ESMO-MCBS v1.1 for myelodysplastic syndrome (n=10)

  Medication                                 Trial name    Setting                                                                              Primary outcome                      PFS control   PFS gain     PFS HR              OS control            OS gain      OS HR               RR (DOR)                    QOL                   Toxicity   ESMO-MCBS score   ESMO-MCBS form   Reference
  ------------------------------------------ ------------- ------------------------------------------------------------------------------------ ------------------------------------ ------------- ------------ ------------------- --------------------- ------------ ------------------- --------------------------- --------------------- ---------- ----------------- ---------------- -----------
  **Azacitidine versus SOC**                 AZA-MDS-001   High-risk MDS                                                                        OS                                                                                  15 months             9.5 months   0.58 (0.43--0.77)                                                                4                 2a               [@R105]
  **Decitabine versus SOC**                                MDS FAB (IPSS ≥0.5)                                                                  Coprimary ORR and PFS                7.8 months    4.3 months   0.58 (0.37--0.91)                                                                                      Improved (+1 point)              4                 2b               [@R106]
  **Lenalidomide (10 mg/5 mg) versus SOC**   LEN-MDS-004   Transfusion-dependent patients with low-risk/intermediate-risk MDS del5q (IPSS ≤1)   RR (RBC-TI)                                                                                                                                                                                                                                [@R107]
  10 mg                                                                                                                                                                                                                             56% vs 6%, gain 50%                                    2                           2c                                                                  
  5 mg                                                                                                                                                                                                                              43% vs 6%, gain 37%                                    2                           2c                                                                  
  **Lenalidomide versus SOC**                LEN-MDS-005   MDS-WHO (IPSS ≤1)                                                                    RR (RBC-TI at ≥8 weeks)                                                                                                                    26.9% vs 2.5%, gain 24.4%   Improved                         2                 2c               [@R108]
  **Antithymocyte globulin versus SOC**      SAKK 33/99    MDS \<10% bone marrow blasts                                                         RR at 6 months                                                                                                                             29% vs 9%, gain 20%                                          2                 2c               [@R109]
  **rHuEPO versus SOC**                      ICSG          MDS \<10% bone marrow blasts                                                         RR (TI)                                                                                                                                    37% vs 11%, gain 26%                                         2                 2c               [@R110]
  **rHuEPO versus ±** **GCSF**                             MDS-FAB (IPSS ≤0.5)                                                                  RR (TI)                                                                                                                                    73% vs 40%, gain 33%                                         2                 2c               [@R111]
  **EPO versus SOC**                         E1996         MDS \<10% bone marrow blasts                                                         RR (IWG 2000 modified)                                                                                                                     36% vs 10%, gain 26%                                         2                 2c               [@R112]
  **rHuEPO +GCSF versus SOC**                GFM           MDS \<10% bone marrow blasts                                                         RR (IWG 2006 stringently modified)                                                                                                         42% vs 0%, gain 42%                                          2                 2c               [@R113]
  **Darbepoetin versus SOC**                               MDS-WHO IPSS ≤1                                                                      RBC transfusion incidence                                                                                                                  59% vs 36%, gain 23%                                         2                 2c               [@R114]

del5q, 5 q deletion; DOR, duration of response;ESMO-MCBS v1.1, European Society for Medical Oncology---Magnitude of Clinical Benefit Scale, version 1.1; FAB, French--American--British classification for MDS; GCS-F, granulocyte-stimulating factor; IPSS, International Prognostic Scoring System; IWG, International Working Group; MDS, myelodysplastic syndrome;ORR, overall response rate; OS, overall survival;PFS, progression-free survival; QOL, quality of life; RBC-TI, red blood cell transfusion independency; rHuEPO, recombinant human erythropoietin; RR, response rate; SOC, standard of care; TI, transfusion independency.

*Scorability*: All studies incorporated required data for evaluation using the ESMO-MCBS v1.1. Clinical benefit measure was, however, partly confounded by the heterogeneity of the available definitions of haematological response and their clinical meaningfulness.

*Reasonableness*: In the two studies evaluating hypomethylating agents in intermediate-risk/high-risk patients,[@R105] the ESMO-MCBS v1.1 graded them with substantial benefit based on either PFS gain or OS gain with improved QOL. In lower risk patients, the remaining eight studies included randomised trials investigating erythropoietin-stimulating agents, lenalidomide in MDS with del(5q) or non-del(5q) and immunosuppressive therapy with antithymocyte globulin plus cyclosporine, compared with best supportive care.[@R107] All studies were evaluated based on response rates, but they used a range of different and inconstant criteria, some using International Working Group, or modifications thereof, and other study-specific criteria such as transfusion requirements. All these studies resulted in a final ESMO-MCSB v1.1 score of 2. In one of these studies[@R108] QOL was evaluated and demonstrated to have improved but this was not reflected in grading since there is no QOL bonus for studies in which response rate is the primary outcome.

*Shortcomings:* The EHA working group identified one shortcoming derived from these evaluations:

1.  In studies evaluating response rate as a primary endpoint, there is no provision of QOL bonus if improved QOL is demonstrated as a secondary outcome.

Discussion {#s4}
==========

The EHA with currently more than 5000 members is the largest European-based haematology association. In addition to its educational mission, it has a public policy and advocacy role that engages stakeholders, including patient representatives, to improve patient care and to raise awareness for haematology as a distinct medical discipline with specific needs.[@R115] Reflecting these goals, EHA has observed the development of the ESMO-MCBS and its broad utility in solid tumour oncology with great interest, and in the absence of a value tool validated for malignant haematology, we sought to investigate the applicability of the ESMO-MCBS v1.1 as a first step to the development of a version validated for HMs.

There are several major differences in the behaviour of HMs as compared with solid tumour cancers. These differences arise largely from the more variable natural history of HMs which can range from fulminant (acute leukaemia and high-grade lymphomas) to almost benign (low-grade MDS). Furthermore, many of these malignant haematological diseases, even when they are not cured, they are characterised by very long PFS and OS that are rarely seen among incurable solid tumour malignancies. Finally, the endpoints used in the studies of treatments for HMs are sometimes different to those used in solid tumours and in some instances, such as CML, they are even disease-specific. Consequently, at the outset of this project we did not know if ESMO-MCBS v1.1 could be applied to studies in HMs, and if the grading of studies would generate grades considered reasonable by experts in the relevant diseases.

This evaluation of the behaviour of the ESMO-MCBS v1.1 in the grading of 80 studies across the full spectrum of HMs has demonstrated that the ESMO-MCBS v1.1 is widely applicable for the overwhelming majority of analysed studies (90% scoreable studies) and that the generated scores were generally adjudicated by clinical experts to reasonably accord with their evaluation of the magnitude of clinical benefit. In 5 of the 80 studies (6%), the ESMO-MCBS could not be applied at all[@R21] and in 3 more studies (4%), it could not be applied to one of the evaluable parameters.[@R68] In the evaluation of imatinib in CML,[@R36] it generated scores that were considered to under-represent the true value of the intervention in the opinion of experts in the evaluated diseases.

Based on the analysis of the scorability of studies and the reasonableness of the generated results, this field testing identified six shortcomings in the current version of the ESMO-MCBS that will require redress to improve the applicability and reasonableness of ESMO-MCBS scoring for malignant haematological conditions.

1.  Regarding single-arm studies with curative intent, such as CAR T-cell salvage therapies, the ESMO-MCBS v1.1 does not have a form to grade single-arm treatments with curative intent.

2.  Regarding relatively indolent conditions with a very long PFS (or EFS) or OS such as CLL, CML, indolent lymphoma and MM, there is no mechanism to credit strong interim gains when the median of the control arm has not yet been reached.

3.  The capitation of PFS at a maximal preliminary grade of 3, with provision for an upgrade based on tail of the curve only when there is a plateau in the arm with the study medication, may undervalue treatments with substantial late PFS gain but with no plateauing of the curves.

4.  Regarding the standard molecular surrogate endpoints used for CML, the surrogacy of complete cytogenic response and level 4--5 MMR must be acknowledged and incorporated.

5.  The scale does not make provision for the grading of non-inferiority studies based on response rate criteria.

6.  In studies evaluating response rate as a primary endpoint, there is no provision of QOL bonus if improved QOL is demonstrated as a secondary outcome.

Finally, it must be acknowledged that the results of the scale may not be reasonable for some of the least malignant of the HMs such as low-risk MDS. Most of the studies for MDS were evaluated based on response rates, but there was heterogeneity of the available definitions of haematological response and their clinical meaningfulness. This underlines the need for a stand-alone form regarding studies with such heterogeneity in their response rates.

ESMO and the EHA are committed to the development of a version of the ESMO-MCBS that is validated for HMs. Based on the findings of this study, a revised version of the ESMO-MCBS will be developed to address the identified shortcomings in the current version of the scale regarding the assessment of HMs. This development process will incorporate all the usual stringencies for accountability of reasonableness that have characterised the development of the ESMO-MCBS. This, thus far, included field testing, statistical modelling, evaluation for reasonableness and openness to appeal and revision. Applying such a scale will support future decision-making and will provide insights that could be helpful in the design of future clinical trials.
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